Caris Life Sciences reported finalized Achieve I results for its multi-cancer early detection blood test Caris Detect, updating performance metrics for sensitivity and specificity across cancer stages. The 3,014-patient study included evaluable patients based on high-risk screening and symptomatic or imaging-driven detection, with stage I–IV sensitivity reported and asymptomatic specificity at 99.2%. Caris said the dataset supports a Q2 2026 launch timeline.